Study on Targeted Drugs for Non-Small Cell NSCLC with PD-1PD-L1 Signaling Pathway

To study the biological function and clinical significance of PD-1/PD-L1 representation in non-small cell lung cancer (NSCLC), and the representation and correlation of PD-1/PD-L1 and epidermal growth factor receptor (EGFR) in NSCLC.

The pathological specimens and clinical data of 108 patients with NSCLC were collected. The representation of PD-1/PD-L1 was detected by immunohistochemistry, and the representation of EGFR was detected by PCR. Logistic regression analysis was used to assess the correlation between PD-1/PD-L1 and EGFR.

The representations of PD-L1 and PD-1 in NSCLC tissues were higher than those in normal lung tissues (P<0.05), and the positive rates were 53.70% and 55.56% respectively, which were related to lymph node metastasis and TNM staging (P<0.05).

The risk of EGFR mutation in NSCLC patients is high, which is closely related to the positive of PD1/PD-L1. PD1/PD-L1 can be used as a predictor of EGFR mutation.